Clinical Trial Update: DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs [Phase 2]

View source ↗

Summary

A Phase 2 trial of datopotamab deruxtecan (DATO-BASE) for breast cancer with brain metastases is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Datopotamab Deruxtecan (datopotamab deruxtecan)

Snippet

Sponsor: Sarah Sammons, MD | Conditions: Breast Cancer, Breast Cancer Female | Phase 2 | Status: RECRUITING